ILONOV

ILONOV is a french-swiss biotech company developing first-in-class biotherapies for the treatment of diabetes and metabolic disorders. Our innovation is rooted in the discovery of the therapeutic potential of a unique myokine, ILV-001, secreted by human skeletal muscle during physical activity. Preclinical studies conducted ex vivo and in vivo have demonstrated that our drug candidate restores insulin secretion and the extracellular matrix environment of pancreatic islets. ILV-001 acts through novel signaling pathways, and the biology of its target receptors remains largely unexplored. This opens opportunities for the development of multiple future therapeutics, while supporting a robust and defensible patent strategy for ILONOV.